EXICURE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
EXICURE, INC. (XCUR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 3.83% for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2025-03-18
- EXICURE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-03-31 was 3.83%.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-03-31 was 1.12%, a 33.33% decline year-over-year.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2020-03-31 was 1.68%.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 3.83%, a 7.58% increase from fiscal 2022.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.56%, a 217.86% increase from fiscal 2021.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 1.12%.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2017 was 2.17%, a 3.13% decline from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2023-12-31 | 3.83% 10-K · filed 2025-03-18 | |||
| 2023-09-30 | 3.83% 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | 3.83% 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | 3.83% 10-Q · filed 2024-06-17 | |||
| 2022-12-31 | 3.56% 10-K · filed 2024-06-06 | |||
| 2022-09-30 | 3.56% 10-Q · filed 2024-05-16 | |||
| 2022-06-30 | 3.56% 10-Q/A · filed 2024-06-06 | |||
| 2021-12-31 | 1.12% 10-K · filed 2023-03-27 | |||
| 2021-09-30 | 1.12% 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | 1.12% 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | 1.12% 10-Q · filed 2022-05-16 | |||
| 2020-09-30 | 1.68% 10-Q · filed 2021-11-19 | |||
| 2020-06-30 | 1.68% 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | 1.68% 10-Q · filed 2021-05-12 | |||
| 2019-09-30 | 2.56% 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | 2.56% 10-Q · filed 2019-08-08 | |||
| 2018-09-30 | 2.87% 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | 2.86% 10-Q · filed 2019-08-08 | |||
| 2017-12-31 | 2.17% 10-K · filed 2018-03-09 | |||
| 2016-12-31 | 2.24% 10-K · filed 2018-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |